Larimar Therapeutics (LRMR) Expected to Announce Earnings on Wednesday

Larimar Therapeutics (NASDAQ:LRMR) is projected to release its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Larimar Therapeutics to post earnings of ($0.49) per share for the quarter.

Larimar Therapeutics Price Performance

NASDAQ LRMR opened at $3.44 on Monday. Larimar Therapeutics has a 1 year low of $1.61 and a 1 year high of $9.50. The firm has a market cap of $220.26 million, a price-to-earnings ratio of -2.31 and a beta of 0.93. The company has a fifty day moving average price of $2.99 and a 200-day moving average price of $2.76.

Analysts Set New Price Targets

Several research firms have recently issued reports on LRMR. Guggenheim reiterated a “buy” rating and issued a $26.00 target price on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. Wedbush reduced their price target on shares of Larimar Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, June 24th. Finally, Citigroup restated a “buy” rating on shares of Larimar Therapeutics in a report on Tuesday, June 24th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $18.50.

Institutional Trading of Larimar Therapeutics

A number of large investors have recently added to or reduced their stakes in LRMR. AQR Capital Management LLC purchased a new stake in Larimar Therapeutics during the first quarter worth about $241,000. Acadian Asset Management LLC bought a new position in Larimar Therapeutics during the first quarter worth about $113,000. Finally, Rhumbline Advisers boosted its position in Larimar Therapeutics by 15.7% during the first quarter. Rhumbline Advisers now owns 65,018 shares of the company’s stock worth $140,000 after purchasing an additional 8,818 shares during the period. Hedge funds and other institutional investors own 91.92% of the company’s stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.